Company intelligence / Profile preview

Nippon Zenyaku Kogyo Co., Ltd.

Koriyama, Fukushima Prefecture, Japanzenoaq.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has several approved drugs including Rituximab (for liver transplant rejection), Liranaftate (for tinea corporis), and Sobuzoxane (for lymphoma). They also have TCN-032 in Phase 2 for influenza and Ismidenon in preclinical stage for memory disorders.

Therapeutic areas: ImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Small molecule drugsMonoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

4 assets

ZSTK3744

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Vetoquinol SA (joint venture: Vetoquinol-Zenoaq K.K.)NexvetNippon Biologicals Inc.Zinpro Animal Nutrition Japan K.K.Merial

Beyond the preview

Go deeper on Nippon Zenyaku Kogyo Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nippon Zenyaku Kogyo Co., Ltd..

Explore the full profile